Drugs / PENBRAYA
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Penbraya | — | 2025-01-20 | europa.eu ↗ |
| Approved | EU (EMA) | Penbraya | — | 2024-11-14 | europa.eu ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07197762 | Nov 2025 → Dec 2026 expected | meningococcal infection | Emory University | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-20 | Pfizer | FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents pfizer.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PENBRAYA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07197762 ↗ |
| Modality | Vaccine | “PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y.” NCT07197762 ↗ |
| Route | Intramuscular | “This will be administered intramuscularly in the deltoid.” NCT07197762 ↗ |